OncoSec Medical (NSDQ:ONCS) said today that it inked a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of its ImmunoPulse IL-12 electroporation device with Merck’s Keytruda therapy in a Phase II clinical trial.
The trial aims to evaluate the drug-device combination in patients with metastatic melanoma – specifically patients who experienced disease progression after previous treatment with an anti-PD-1 therapy.
OncoSec’s electroporation device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver cancer-killing drugs.
Get the full story at our sister site, Drug Delivery Business News.
The post OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma appeared first on MassDevice.